Driver Bioengineering
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Driver Bioengineering - overview
Established
2015
Location
South San Francisco, CA, US
Primary Industry
Biotechnology
About
Founded in 2015 and based in California, US, Driver Bioengineering, Inc. , doing business as Chimera Bioengineering, operates as a biotechnology company. The company was founded by its Chief Operating Officer, Benjamin Wang, Chief Science Officer, Gusti Zeiner, and Christina Smolke. In February 2022, Driver Bioengineering, Inc.
raised an additional USD 23. 2 million in Series A financing from unspecified investors. The Series A funding values Driver Bioengineering, Inc. at USD 31.
25 million post-money. As of 2022, the company is led by its CEO, Vlad Hogenhuis. Driver Bioengineering conducts research on engineered immune cells called CAR T (Chimeric Antigen Receptor T-cells) to use as a cell therapy to help cancer patients. The company employs RNA engineering and cellular immunotherapy to develop test drug-responsive control systems.
Its offerings include Gold Platform™, which contains Gold Control™, Transgene Vector, Therapeutic Payload, and Mercury? ™ to control gene expression in any cell therapy.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Information Services
Website
www.chimera.bio
Company Stage
Series A
Total Amount Raised
Subscriber access only
Driver Bioengineering - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.